A black box - Improving quality control risk management in biopharmaceutical transportation (2019)

Biopharmaceutical manufacturers have molecular defect risks to consider when transporting biopharmaceuticals along global supply chains to points-of-care. Analytical technology improvements are on the horizon to contribute to risk management. Overall, risks to patient safety, drug effectiveness and company cost recovery will reduce.

I was on vacation in Dubai last week and went to the top of the Burj Khalifa, the tallest building in the world at just over half a mile high. I looked down and took this photo of the road network around it. Absolutely mind-boggling how they construct all these huge roads and networks.. Photo by Nick Fewings, Unsplash.

Home>Food for thought>A black box - Improving quality control risk management in biopharmaceutical transportation (2019)

_________________________________

Click on the image to open the article in PDF format.

This website is using cookies to provide a good browsing experience

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

This website is using cookies to provide a good browsing experience

Necessary
Functional
Analytics
Marketing
External Media

Your cookie preferences have been saved.